Axovant Sciences (AXON) says Lunbeck study failure was expected - Bloomberg

September 22, 2016 3:40 PM EDT
Get Alerts AXON Hot Sheet
Trade AXON Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Axovant Sciences (NYSE: AXON) says Lunbeck study failure in Alzheimer's disease was expected, according to Bloomberg, citing a company email.

Axovant noted that weak efficacy in phase 3 wasn't surprising.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment